Corestem Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
371
- Stock Symbol
-
166480
- Investments
-
1
- Share Price
-
$10.14
- (As of Friday Closing)
Corestem General Information
Description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact Information
Website
www.corestemchemon.comCorporate Office
- Number 1008, Number 902, Number 401 (the holy one, SK Techno Building)
- 133-710 gu, holy days 55
- Seoul, 04779
- South Korea
Corporate Office
- Number 1008, Number 902, Number 401 (the holy one, SK Techno Building)
- 133-710 gu, holy days 55
- Seoul, 04779
- South Korea
Corestem Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.14 | $10.17 | $3.88 - $10.79 | $251M | 24.8M | 159K | -$1.18 |
Corestem Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 213,302 | 127,692 | 142,465 | 235,874 |
| Revenue | 22,797 | 25,743 | 35,506 | 26,401 |
| EBITDA | (19,179) | (7,051) | 9,617 | 3,290 |
| Net Income | (25,955) | (13,516) | (1,747) | (6,110) |
| Total Assets | 69,191 | 60,986 | 61,013 | 114,627 |
| Total Debt | 27,215 | 25,430 | 14,598 | 23,226 |
Corestem Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corestem Executive Team (2)
| Name | Title | Board Seat |
|---|---|---|
| Kyung Suk Kim | Co-Chief Executive Officer |
Corestem Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Corestem Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ChemOn | 01-Dec-2022 | Laboratory Services (Healthcare) |
Corestem FAQs
-
When was Corestem founded?
Corestem was founded in 2003.
-
Who is the CEO of Corestem?
Kyung Suk Kim is the CEO of Corestem.
-
Where is Corestem headquartered?
Corestem is headquartered in Seoul, South Korea.
-
What is the size of Corestem?
Corestem has 371 total employees.
-
What industry is Corestem in?
Corestem’s primary industry is Drug Discovery.
-
Is Corestem a private or public company?
Corestem is a Public company.
-
What is Corestem’s stock symbol?
The ticker symbol for Corestem is 166480.
-
What is the current stock price of Corestem?
As of 11-Oct-2024 the stock price of Corestem is $10.14.
-
What is the current market cap of Corestem?
The current market capitalization of Corestem is $251M.
-
What is Corestem’s current revenue?
The trailing twelve month revenue for Corestem is $22.8M.
-
What is Corestem’s annual earnings per share (EPS)?
Corestem’s EPS for 12 months was -$1.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
